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Echocardiography in Heart Failure
Applications, Utility, and New Horizons
James N. Kirkpatrick, MD,* Mani A. Vannan, MBBS, FACC,†
Jagat Narula, MBBS, PHD, FACC, FAHA,† Roberto M. Lang, MD, FACC, FAHA, FESC, FASE‡
Philadelphia, Pennsylvania; Orange, California; and Chicago, Illinois
Echocardiography is well qualified to meet the growing need for noninvasive imaging in the expanding heart failure
(HF) population. The recently-released American College of Cardiology/American Heart Association guidelines for the
diagnosis and management of HF labeled echocardiography “the single most useful diagnostic test in the evaluation
of patients with HF. . .,” because of its ability to accurately and noninvasively provide measures of ventricular function
and assess causes of structural heart disease. It can also detect and define the hemodynamic and morphologic
changes in HF over time and might be equivalent to invasive measures in guiding therapy. In this article we will dis-
cuss: 1) the clinical uses of echocardiography in HF and their prognostic value; 2) the use of echocardiography to
guide treatment in HF patients; and 3) promising future techniques for echocardiographic-based imaging in HF. In
addition, we will highlight some of the limitations of echocardiography. (J Am Coll Cardiol 2007;50:381–96)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.048f
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“
cchocardiography is, according to the recently released
merican College of Cardiology/American Heart Associa-
ion (ACC/AHA) guidelines for the diagnosis and man-
gement of heart failure (HF), “the single most useful
iagnostic test in the evaluation of patients with HF. . .,”
ecause of its ability to accurately and noninvasively provide
easures of ventricular function and assess causes of struc-
ural heart disease (1). An estimated 5 million people have
F, and their ranks are increased by an estimated 550,000
ach year (2). Heart failure hospital stays have increased
50% over the last 20 years (2). The lifetime risk of
eveloping HF has been estimated at 20% for the U.S.
opulation. And, although ischemic heart disease is the
ost common cause of HF, up to 11% of the population
ithout evidence for coronary artery disease will also de-
elop HF (3).
Heart failure is classically described as left ventricular
LV) dysfunction leading to congestion and reduced sys-
emic perfusion, most often manifesting symptomatically as
yspnea and fatigue. After an insult to the myocardium, the
V progressively dilates or hypertrophies, a process followed
y spherical remodeling. These morphologic changes cause
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007, accepted March 29, 2007.urther stress on the myocardium by increasing wall tension
nd cause or exacerbate mitral regurgitation, which, in turn,
esults in further dilatation and contractile dysfunction in a
icious cycle (1). Such remodeling is often the final common
athway for many although not all etiologies of HF.
Because this morphologic process begins before the
nset of symptoms, the recent HF guidelines place
pecial emphasis on detecting subclinical LV systolic and
iastolic dysfunction (1,4). Several studies have empha-
ized that standard physical examination maneuvers are
uboptimal in detecting either systolic or diastolic LV
ysfunction, especially in the preclinical phase. Similarly,
hysical examination is limited in its ability to accurately
haracterize the volume and cardiac output status in
atients with LV dysfunction (5,6). As a rapid and
ccurate modality, echocardiography can improve the
oninvasive detection and definition of the hemodynamic
nd morphologic changes in HF. Echocardiography
ight also be equivalent to catheter-based techniques in
uiding therapy and improving outcomes, without the
isks and cost of invasive measures (5).
In this review we will discuss: 1) the clinical uses of
chocardiography in HF and their prognostic value; 2)
he use of echocardiography to guide treatment in HF
atients; and 3) promising future echocardiographic
echniques for cardiac imaging in HF. We will also
ighlight some of the limitations of echocardiography
outlined in Tables 1 and 2). We will use the term
echocardiography” in a general sense to refer to all
ardiac ultrasound imaging techniques, including-mode, 2- and 3-dimensional imaging, and spectral
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Echocardiographic Applications in HF July 31, 2007:381–96and color Doppler, which com-
prise the comprehensive sono-
graphic assessment of cardiac
structure and function.
Clinical Measurements
and Prognosis
Used for many years to provide
structural correlates to the clini-
cal picture of HF, echocardiog-
raphy can also measure multiple
clinically important parameters
of cardiac function, including he-
modynamic status and LV ejec-
tion fraction (EF), volumes, and
mass.
Hemodynamics. Intracardiac pres-
sure measurements have tradition-
ally required invasive methods.
This limitation, which also pre-
cludes serial measurements out-
side of the intensive care context,
can often be circumvented with
the use of echocardiographic
techniques. In selected patients,
chocardiography might be a noninvasive surrogate (Fig. 1).
troke volume and cardiac output can be estimated from the
elocity time integral obtained by pulse wave Doppler
ecordings in the left ventricular outflow tract (LVOT),
ultiplied by the LVOT area. Figure 1 illustrates the
chocardiographic estimates of right atrial pressure, right
entricular systolic pressure/pulmonary artery systolic pres-
ure, and pulmonary artery mean and diastolic pressures
7–9). All of these measurements require adequate imaging
indows and parallel alignment of the Doppler cursor with
lood flow to avoid underestimation of Doppler jet velocity
nd calculated pressure. Stroke volume as measured in the
VOT is overestimated in the presence of significant aortic
nsufficiency. Small errors in the measurement of LVOT
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
EF  ejection fraction
HF  heart failure
ICD  implantable
cardioverter-defibrillator
LV  left
ventricle/ventricular
LVEDP  left ventricular
end-diastolic pressure
LVOT  left ventricular
outflow tract
TDI  tissue Doppler
imaging
SF  systolic fraction
of pulmonary venous
forward flow
VAD  ventricular assist
device
Vp  flow propagation
slope of early diastolic
left ventricular filling
Evaluation of Standard Doppler Echocardiograph
Table 1 Evaluation of Standard Doppler Ech
Technique Strengths
Doppler (hemodynamics) 1. Facile
2. Rapid
3. On-line
Doppler (diastolic function) 1. Facile
2. Rapid
3. On-line
4. Prognostic
2D EF, dimensions and
mass
1. Facile
2. Rapid
3. Prognostic
4. On-line2D  2-dimensional; AI  aortic insufficiency; EF  ejection fraction; HF  hiameter lead to large errors in the calculation of LVOT
rea. Pulmonary artery pressure estimates require the pres-
nce of tricuspid valve regurgitation for systolic pressure and
ulmonic valve regurgitation for mean and diastolic pres-
ures as well as an accurate estimate of right atrial pres-
ure (10).
A variety of echocardiographic techniques can deter-
ine abnormal diastolic function, increased left atrial
ressure and left ventricular end-diastolic pressure
LVEDP). These measurements have demonstrated con-
iderable prognostic value in symptomatic and asymp-
omatic patients with either preserved or abnormal LV
ystolic function (11). The adverse prognosis associated
ith systolic dysfunction is well described, but isolated
iastolic HF also carries a poor prognosis, including
uture development of systolic HF (12).
Diastolic function can be characterized according to
everity. Mild diastolic dysfunction—abnormal LV relax-
tion—can be detected via a decrease in early diastolic flow
elocity (E-wave) and a greater reliance on atrial contraction
A-wave) to fill the LV (E/A 1). Moderate diastolic
ysfunction—“pseudonormalization”—reflects increasing
eft atrial pressure at the onset of diastole and an increase in
arly diastolic flow velocity to a level near that of normal
lling (E/A 1 to 1.5). Severe diastolic dysfunction—
estrictive filling—occurs when left atrial pressure is further
levated such that early diastolic flow is extremely rapid and
eft atrial and LV pressures equalize quickly during early
iastole (E/A 2, DT 115 to 150 ms). Reduction in
reload with the Valsalva maneuver can unmask diastolic
ysfunction by changing a pseudonormalized pattern to an
bnormal relaxation pattern or a restrictive pattern to a
seudonormalized one (13,14). Persistence of a restrictive
lling pattern during the Valsalva maneuver or on follow-up
chocardiogram after HF therapy portends a particularly
rim prognosis, as shown by Pinamonti et al. (15) and
thers. These traditional techniques, however, are depen-
ent on heart rate and loading conditions and lack validity
n patients with preserved EF.
chniques in HF
iographic Techniques in HF
Limitations
1. Requires parallel alignment of Doppler beam
2. Pulmonary and tricuspid valve regurgitation
not always present
3. Stroke volume measurement from LVOT
overestimated in significant AI
1. Requires parallel alignment of Doppler beam
2. Heart rate dependent
3. Load dependent
1. Dependent on image quality
2. Foreshortening common
3. High inter- and intra-observer variability
4. Requires geometric assumptions
5. Does not correlate well with clinical statusic Te
ocardeart failure; LVOT  left ventricular outflow tract.
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July 31, 2007:381–96 Echocardiographic Applications in HFAdditional parameters such as: 1) an abnormal ratio of
he systolic and diastolic velocities of pulmonary venous
nflow (S/D 1); 2) a systolic fraction of pulmonary venous
orward flow (SF) of 40%; and 3) an early LV filling flow
ropagation slope (Vp) of 45 cm/s are less dependent on
oading conditions and heart rate and have been shown to be
obust predictors of high LV filling pressures and cardio-
ascular mortality (16,17). These measures are limited by
nability to adequately image the pulmonary veins in some
atients and by the limited reproducibility of Vp. A ratio of
eak early mitral inflow velocity (E) to peak early diastolic
yocardial velocity (E’) of 8 predicts an LVEDP of 15
m Hg, whereas a ratio of 15 predicts an elevated
VEDP (15 mm Hg) (Fig. 1D) (14). The ratio of peak
arly mitral inflow velocity to slope of the propagation
elocity (E/Vp) of 1.5 predicts a LVEDP 15 mm Hg
nd has been shown to have prognostic value in post-
yocardial infarction patients (18). Increased left atrial
olumes (32 ml/m2), which are usually larger in diastolic
ompared with systolic HF, have been shown to predict
orbidity (19). Among multiple diastolic parameters in
atients with a broad range of EF and degrees of mitral
egurgitation, Rossi et al. (20) have demonstrated that a
30-ms difference between pulmonary vein atrial flow
eversal and mitral A-wave durations was the most sensitive
redictor of elevated LVEDP 18 mm Hg. Interestingly,
/E’ has proven superior to brain natriuretic peptide (BNP)
evels in diagnosing volume overload, even in patients with
reserved systolic function (21,22). Tables 3 and 4 list
atient population, Doppler modality, cutoff values, and
utcome measures used in a variety of prognostic studies of
iastolic function and filling pressures (12,15–17,19,23–
1). Figures 2A and 2B depict strategies for using Doppler
echniques to noninvasively estimate filling pressures and
haracterize the severity of diastolic dysfunction in patients
ith reduced EF. The strategies reflect the fact that syn-
hesis of multiple parameters is often required to give an
valuation of Novel Doppler Echocardiographic Techniques in HF
Table 2 Evaluation of Novel Doppler Echocardiographic Techniq
Technique Strength
Real time 3D for EF and volumes 1. Eliminates foreshor
2. Geometric assumpt
required
3. Simultaneous asses
wall segments
Tissue Doppler, strain, and strain rate 1. Prognostic
2. Most parameters lo
3. Widely available (tis
4. Less dependent on
Tissue tracking 1. Not angle dependen
2. Able to assess torsi
D  3-dimensional; TDI  tissue Doppler imaging; other abbreviations as in Table 1.ssessment of filling dynamics, particularly when poor scoustic windows might limit the ability to make every
easurement.
he myocardial performance index. The myocardial per-
ormance index (better known as the Tei index) is a simple
oppler parameter that provides global assessment of sys-
olic and diastolic function. The Tei index consists of the
atio of the isovolumic contraction  isovolumic relaxation
imes/the ejection time—all parameters that can be ob-
ained from Doppler interrogation. The Tei index is inde-
endent of heart rate and blood pressure, applies to left and
ight ventricular systolic and diastolic dysfunction, does not
ely on geometric assumptions, and is highly reproducible,
lthough normal values vary with age (42,43). It has been
orrelated with invasively measured changes in LV dP/dt
44). The prognostic value of the Tei index was initially
ested in patients with infiltrative cardiomyopathy and
ulmonary hypertension (45). It has subsequently been
alidated in patients with dilated cardiomyopathy, with a
alue of 0.77 proving superior to EF in predicting cardiac
eath and disease severity (46). The Tei index also proved
eneficial in predicting the development of HF in a cohort
f elderly men without baseline LV dysfunction (47) and in
redicting the lack of clinical response to medical treatment
n a study including both patients with systolic HF and HF
ith preserved systolic function (48). Because adequate
oppler images can often be acquired when 2-dimensional
2D) image quality is suboptimal, the Tei index might be
articularly useful when other measures of left and right
entricular function are obscured or indeterminate.
F and dimensions. Traditionally, EF measurements
ave been visually estimated with important limitations
f subjectivity and dependence on highly trained expert
nterpretation for accuracy. Although symptoms guide the
ajority of HF management decisions, precise and repro-
ucible EF measurements play an increasingly important
ole in guiding important interventions. Consequently,
uantified, objective measurements of LV systolic function
in HF
Limitations
t
of all
1. Highly dependent on image quality
2. Extra expense of software and probe
3. Incremental value over 2D not well established
4. Sonographer expertise required
5. Not widely available
pendent
locity)
quality
1. Angle dependent
2. Strain and strain rate require off-line analysis
3. Low signal/noise ratio
echanics
1. Extra expense of software
2. Incremental value over TDI not well established
3. Speckles move in and out of plane (requires
mathematical assumptions to compensate)
4. Requires off-line analysis
5. Not widely availableues
s
tening
ions no
sment
ad inde
sue ve
image
t
onal mhould become standard practice in echocardiography. Al-
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Echocardiographic Applications in HF July 31, 2007:381–96hough fractional shortening measured from M-mode
racings can quantify LV function, it is valid only in a
ymmetrically contracting heart without regional variability
nd is therefore inappropriate for the remodeled ventricles
f many HF patients. The new guidelines from the Amer-
can Society of Echocardiography (ASE) advocate the
iplane method of discs for EF quantification and discour-
ge the use of M-mode measurements that rely on geo-
etric assumptions to convert linear measurements to
-dimensional (3D) volumes (49). An alternative method
or volume calculation, useful when the endocardium is not
ell defined, is the area-length method. This method
ssumes a bullet-shaped ventricle and involves planimetry of
he mid-ventricle short-axis area and the annulus-to-apex
ength in systole and diastole. With either 2D method, the
ew ASE guidelines define an abnormal EF as 55%, with
he cutoffs for moderately abnormal and severely abnormal
Figure 1 Illustration of “Echo Right Heart Catheterization”
(A) Inferior vena caval (IVC) size and degree of collapse yields a range of right atri
50% collapse  RAP 0 to 5 mm Hg; 1.7 cm with 50% collapse  RAP 6 to 1
RAP 15 mm Hg (51). (B) The tricuspid regurgitant velocity (TR Vel) is used to es
tolic pressure, in the absence of pulmonic stenosis). (C) The maximal pulmonic va
(PAPm). The end diastolic pulmonic regurgitant velocity is used to estimate diasto
mitral valve annular motion (E’-wave) ratio 8 or 15 is calculated to assess PCW
inflow velocity to early diastolic velocity of the mitral valve annulus; IVCCI  inferio
 pulmonic valve regurgitant velocity; RVSP  right ventricular systolic pressure.t 44% and 30%, respectively. The reference ranges for LV Timensions are best indexed to body surface area, with
eference ranges 2.4 to 3.2 cm/m2 and cutoff values of 3.5
nd 3.8 cm/m2 for moderate and severe dilation, respec-
ively (49).
Image quality in patients with poor acoustic windows has
raditionally played a major role in limiting the accuracy of
uantification of LV volumes and EF. Tissue harmonic
maging with and without echocardiographic contrast for
V cavity opacification has improved the accuracy and
eproducibility of EF measurements (50,51). This method
as enabled the accurate assessment of LV function in
early all patients, irrespective of body habitus, chest wall
eformities, or pulmonary diseases (52–54) (Fig. 3). Two-
imensional echocardiography, even when employing these
ethods, lacks accuracy compared with the gold standards
f magnetic resonance imaging (MRI) or radionuclide
entriculography for quantification of EF and volumes (55).
sure (RAP): 1.2 cm with full collapse  RAP 0 mm Hg; 1.2 to 1.7 cm with
Hg; 50% collapse  RAP 10 to 15 mm Hg; and 1.7 cm with 0% collapse 
 the systolic right ventricle—right atrium gradient (and the pulmonary artery sys-
gurgitant velocity is used to estimate the mean pulmonary artery pressure
onary artery pressure (PAPd). (D) The early mitral inflow (E-wave)/early diastolic
5 mm Hg or 15 mm Hg, respectively. E/E’  ratio of early diastolic mitral
cava collapsibility index; PCWP  pulmonary capillary wedge pressure; PR Vel.al pres
0 mm
timate
lve re
lic pulm
P 1
r venahe reasons for the consistent underestimation of LV
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July 31, 2007:381–96 Echocardiographic Applications in HFolumes and EF involve reliance on geometric assumptions,
ombined with foreshortening of the LV from transducer
ositioning errors. This underestimation might be overcome
ith the use of 3D echocardiography (56).
Although EF and LV dimensions do not correlate with
F symptoms, exercise capacity, or myocardial oxygen
onsumption (57,58), they do provide crucial prognostic
nformation (59). Morbidity and mortality are closely
inked to both EF and LV volumes in HF patients in
ulticenter trials (60,61). Although influenced by a
yriad of demographic and clinical factors, post-
yocardial infarction prognosis is most powerfully pre-
icted by EF and LV size. Early studies of acute
yocardial infarction survivors using cineangiography
nd radionuclide ventriculography demonstrated EF
40% and increased LV volumes to be predictors of
ubsequent cardiovascular mortality and sudden death
62– 65). More recent studies using echocardiography
ave also found EF and LV volumes to be powerful
rognosticators for major adverse cardiac events (66,67).
he ability of echocardiography to assess global dysfunc-
ion and regional wall motion has aided in the assessment
f the size of myocardial infarctions. This measurement
rognostic Significance of Echocardiographic Diastolic Dysfunction
Table 3 Prognostic Significance of Echocardiographic Diastolic
Modality Patient Population
Mitral inflow Doppler
E/A 2,671 elderly patients, no CVD 
E/A 1,839 hypertensive patients Ag
E/A 3,008 Native Americans 
DT 110 patients, EF 50%, no CAD 
Peak E 2,671 elderly, no CVD Co
DT 571 patients post-AMI 
DT 79 HF patients, no CAD 
M-mode IVRT 185 elderly HF patients 
Pulmonary vein Doppler
PV AR dur  MV A dur 145 LV dysfunction patients 
S/D 115 patients, EF 45% 
Tissue Doppler
E/E’ 250 patients post-AMI 
E/E’ 45 patients, NYHA functional class
III or IV HF
Co
E/E’ 130 chronic HF patients 
E/E’ 110 patients hospitalized with HF 
E’, E/E’ 518 patients referred for echocardiography E’
Systolic mitral annular velocity 185 patients, EF 45% Co
LA volume 1,375 elderly patients with preserved EF 
Flow propagation
E/Vp 67 post-MI patients E/
Vp 125 post-MI patients Vp
New onset event myocardial infarction, sudden cardiac death, unstable angina, revascularizati
nd-stage renal disease.
A  atrial filling velocity; AMI  acute myocardial infarction; CAD  coronary artery disease; CV
arly diastolic filling velocity; E’ tissue Doppler early filling velocity; EF ejection fraction; IVRT
uration; NYHA  New York Heart Association; PV AR dur  pulmonary vein atrial reversal duratiredicts cardiogenic shock (if 40% of the myocardium bs involved), development of chronic HF, and mortality,
espite the fact that myocardial stunning and hibernation
omplicate the prediction of eventual infarct size (68,69).
V mass. Although LV mass has received less attention
n clinical cardiology than EF, it is an important prog-
ostic marker in HF in patients with and without
oronary artery disease (70). This observation in smaller
tudies was confirmed in the echocardiographic substudy
f the SOLVD registry and trials, in which investigators
xamined the effect of LV hypertrophy on clinical out-
omes and found that increased LV mass was associated
ith high mortality and rate of cardiovascular hospital
tays, independent of EF (71). Because population stud-
es suggest that the etiology of HF in African-American
atients is more likely to be hypertensive than ischemic
72), the routine and accurate measurement of LV mass
nd its prognostic significance might be even more salient
n this population.
Left ventricular mass assessment is subject to the same
imitations in reproducibility and accuracy as measurement
f LV dimensions (73). The current ASE guidelines rec-
mmend mass calculation from linear dimensions with the
ubed formula, modeling the LV as a prolated ellipse,
sures: Single Component Studies
unction Measures: Single Component Studies
Cutoff Values Outcome
1.5 Incident HF
heart rate-adjusted ratio below median Cardiovascular events*
1.5 Death or cardiac death
s, persisting after 3 months’ HF treatment Death or transplant at 4 yrs
us Incident HF
s Death at 4 yrs
s Death or transplant
Death
Cardiac death or hospital stay
HF hospital readmission or HF death
at 1 yr
Death
us Predictor of NYHA functional class,
HF hospital stay, cardiac death
Composite: cardiac death, HF hospital
stay, urgent transplant
Cardiac death or hospital readmission
for HF
3–5 cm/s, E/E’20 Cardiac death
us Death or transplant
/m2 Incident HF
.5 Death and HF readmission
cm/s Cardiac death
ke/transient ischemic attack, hospital stay for heart failure (HF), symptomatic aorto-iliac disease,
rdiovascular disease; D  diastolic pulmonary vein wave; DT  deceleration time of E-wave; E 
ntricular relaxation time; LA left atrium; LV left ventricle; MV A durmitral valve atrial wave
systolic pulmonary vein wave; Vp  flow propagation velocity slope.Mea
Dysf
0.7 or
e- and
0.6 or
115 m
ntinuo
130 m
115 m
30 ms
30 ms
1
15
ntinuo
12.5
15
3 or
ntinuo
32 ml
Vp 1
45
on, stro
D  caecause this method has been validated in multiple studies
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Echocardiographic Applications in HF July 31, 2007:381–96ith pathologic correlation. The cubed formula lacks pre-
ision, however, when applied to many HF patients, because
t involves geometric assumptions that are invalid in a
onsymmetrically contracting, remodeled ventricle. Two-
imensional methods, including the truncated ellipsoid and
he area-length formula, might be more appropriate for
istorted ventricles with regional wall motion abnormalities.
Figure 2 Diastolic Filling Parameters and the Prediction
of Normal Versus Elevated Filling Pressure
(A) Prediction of normal versus elevated filling pressure. In patients with preserved
and reduced left ventricular ejection fraction (LVEF), normal filling pressures are
predicted by normal mitral inflow E-wave to tissue Doppler E’-wave ratio (E/E’) and
mitral inflow E-wave to flow propagation ratio (E/Vp) values or intermediate values
with normal left atrium (LA) size, normal pulmonary vein atrial reversal duration
minus mitral inflow A-wave duration (ARdur  Adur), and a minimal change in the
E/A wave ratio with Valsalva. Elevated filling pressures are predicted by elevated
E/E’ and E/Vp values or intermediate values with elevated LA size, prolonged
ARdur  Adur, a substantial change in the E to A valve with Valsalva, or a pro-
longed pulmonary vein D-wave deceleration time (DDT). (B) Degree of diastolic dys-
function. In patients with reduced LVEF, mitral inflow E/A, mitral inflow E-wave
deceleration time (EDT), and isovolumic relaxation time (IVRT) parameters, con-
firmed by pulmonary vein S to D ratio (S/D), systolic fraction of pulmonary venous
forward flow (SF), and DDT can further define filling dynamics by stratifying diastolic
function into “abnormal relaxation” (normal filling pressures), “pseudonormal” (ele-
vated filling pressures), and “restrictive” (very high filling pressures) categories.
Valsalva E/A  change in mitral inflow E to A-wave ratio with Valsalva maneuver.
(Modified from Nagueh SF, Zoghbi WA. Clinical Assessment of LV Diastolic Filling
by Doppler Echocardiography. ACC Current Journal Review. 2001; July/Aug: 49).These methods, however, rely heavily on geometric assump-T M M R R R R R A AR
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July 31, 2007:381–96 Echocardiographic Applications in HFions. Furthermore, as mentioned, these methods are sub-
ect to inaccuracies from foreshortening.
Unlike EF and LV dimensions, LV mass has different
utoff values for men and women and for linear and 2D
ethods. The reference ranges for women are 67 to 162 g
nd 66 to 150 g for the linear and 2D methods, respectively.
ndexed to body surface area, these ranges are 43 to 95 g/m2
nd 44 to 88 g/m2. For men the reference ranges are 88 to
24 g and 96 to 200 g, and 49 to 115 g/m2 and 50 to 102
/m2 (49).
The LV mass increases in the remodeled, failing heart,
ither from increased volumes with myocardial thinning or
rom wall hypertrophy in patients with hypertensive cardio-
yopathy (74). Despite its limitations, the assessment of
V mass provides not only an important research tool to
valuate remodeling but also a precise and prognostically
Figure 3 Contrast Opacification of the Left Ventricular Cavity
(A) Apical 4-chamber views with poor endocardial definition. (B) The same view
with improved endocardial definition after echocardiographic contrast
administration.owerful way to characterize clinical status. wherapeutic Guidance
chocardiography not only provides clinical measures and
rognostic assessments in patients with HF but can also
upply information to guide application of HF therapies.
edications. In addition to the demonstrated benefit of
ngiotensin-converting enzyme (ACE) inhibitors for pa-
ients with both symptomatic and asymptomatic LV dys-
unction (75), beta-blocker drugs are beneficial for almost
ll well-compensated patients with LV systolic dysfunction
76,77), and aldosterone antagonists reduce mortality in
ew York Heart Association functional class III and IV
atients hospitalized for HF with EF 35% and in post-
yocardial infarction patients with EF 40 % (78,79). Not
nly does echocardiographic EF measurement commonly
stablish an indication for these medications but also im-
rovements in EF and LV volumes by echocardiography are
sed as standard measures of therapeutic effect in many
linical trials of HF medications (80,81). Conversely, echo-
ardiography also supplies an assessment tool for the detri-
ental effects on LV function of cardiotoxic medications,
uch as anthracycline chemotherapeutic agents. The EF
ecrements while taking these medications is often an
ndication for discontinuation (82,83).
The strategy of combining echocardiographic assessment
f filling pressures with BNP measurement has definite
rognostic value and might prove one of the most accurate
ays to noninvasively guide fluid management. In a study by
okainish et al. (31), an E/E’ value 15, combined with
NP 250 pg/ml, measured on the day before discharge,
ad incremental power in predicting readmission or cardiac
eath compared with traditional clinical risk factors. If
roven to be cost-effective, echocardiography with BNP
ight become an important strategy for triaging HF pa-
ients in acute care settings, for assessing suitability for
ischarge, or for identifying patients who need more inten-
ive outpatient management.
mplantable cardioverter-defibrillators (ICDs). Recent
tudies have demonstrated the benefit of prophylactic ICD
or the primary prevention of sudden death in patients with
educed EF (84,85). Reimbursement strategies for ICDs
herefore rely on EF as a common parameter for placement
f these devices in HF patients, and echocardiography is
ften employed to assess EF (1). Repeat EF assessment at
0 to 40 days after myocardial infarction and after initiation
f optimal HF medical therapy is necessary to determine
andidacy for ICD. Many patients’ EF rise above 30% to
5% cutoff after a month on an appropriate medical regi-
en, and premature ICD implantation has shown no
enefit (86).
ardiac resynchronization therapy (CRT). Many HF
atients lack coordinated contraction of the LV walls
intraventricular dyssynchrony) and between the right and
eft ventricles (interventricular dyssynchrony). Cardiac re-
ynchronization therapy can restore coordinated contraction
ith demonstrated improvement in symptoms and survival
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Echocardiographic Applications in HF July 31, 2007:381–9687). Current recommendations and reimbursement strate-
ies advocate that only patients with EF 35%, moderate-
o-severe HF symptoms, a widened QRS interval, and sinus
hythm should undergo CRT (1). Nevertheless, it is now
lear that not all patients meeting these criteria will respond
o CRT; furthermore, it has been recently shown that a
ubgroup of patients lacking these criteria could benefit
rom CRT (88). Echocardiographic measurement of dys-
ynchrony can accurately predict beneficial response in the
orm of reverse remodeling (reduction in LV volumes,
mproved EF, and reduced mitral regurgitation) (89), and
chocardiographically demonstrated reverse remodeling
redicts improved survival (90,91). Currently, different
echniques are used to assess dyssynchrony, some of which
re discussed in the following text (92). It remains to be seen
hich measurement or combination of measurements will
rove most accurate in predicting beneficial response to
RT. This is an area of active investigation in the
ROSPECT (Predictors of response to cardiac resynchro-
ization therapy) trial and other studies (93).
itral valve surgery. So-called “functional” mitral regur-
itation in HF has traditionally been ascribed to stretching
f the mitral annulus and malcoaptation of the mitral valve
Figure 4 Left Ventricular Assist Device Cannula Obstruction Fr
(A) Transesophageal echocardiogram in the mid-esophageal 4-chamber view demo
short-axis view demonstrates inflow cannula proximity to an area of hypertrabecula
(arrows). (C) Close-up view in the mid-esophageal 4-chamber view demonstrates a
ous wave Doppler imaging demonstrates high velocities into the inflow cannula, coeaflets. More recent echocardiographic and pathologic
nvestigations have described tethering of the mitral valve
eaflets from remodeling-induced displacement of 1 or both
apillary muscles and structural changes of the mitral valve
tself. These mechanisms rather than annular dilatation
ight be the main determinants of functional mitral regur-
itation (94,95).
The rationale behind repair or replacement of the mitral
alve has been the traditional perspective on functional
itral regurgitation; nonetheless, surgery has demonstrated
fficacy, even in advanced HF (96). But it is not always clear
hether repair or replacement is indicated. Furthermore,
he severity of functional mitral regurgitation can be reduced
y CRT and by ACE inhibitor therapy without surgery,
resumably owing to the effects of reverse remodeling (97).
Traditional echocardiographic evaluation of mitral regur-
itation has significant limitations. The mitral valve annulus
s saddle-shaped and cannot be fully visualized in 2D
maging planes (98). The mitral valve regurgitant jet,
specially when eccentric, is also incompletely visualized in
raditional imaging planes, leading to misclassification of
itral regurgitation severity. Similarly, the geometric as-
umptions involved in calculating mitral regurgitation se-
rabeculation
ing inflow cannula of a left ventricular assist device (arrow). (B) Transgastric
at is consistent with non-compaction of the left ventricular myocardium
a of hypertrabeculation being pulled into the inflow cannula (arrow). (D) Continu-
nt with partial obstruction.om T
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July 31, 2007:381–96 Echocardiographic Applications in HFerity with Doppler flow and color Doppler (e.g., calcula-
ions of effective regurgitant orifice area) lead to inaccuracies
n non-central jets (99,100).
entricular reconstruction surgery. A number of ventric-
lar reconstruction surgeries have been proposed for pa-
ients with ischemic HF and apical dyskinesis or LV
neurysms (101,102). These surgical mechanical techniques
educe ventricular remodeling and have improved both
orbidity and mortality in HF patients in small studies
103,104), but definitive conclusions await the results of
ngoing trials (105). Decision-making for these surgical
rocedures relies heavily on accurate determination of dys-
inesis or akinesis, thinning of the apical segment, de-
ressed EF, coexistence of mitral regurgitation, and volu-
etric measurement (106,107). An elevated LV end systolic
olume index 60 ml/m2, in particular, portends poor
ostoperative survival (108). Echocardiography provides
ccurate preoperative modeling to guide the amount of
yocardium to be excluded or resected (109). And echo-
ardiography provides an important way to judge the effi-
acy of these procedures in improving ventricular remodel-
ng, hemodynamic status, and EF.
entricular assist devices. Ventricular assist devices (left
entricular assist device  LVAD, bi-ventricular assist
evice  bi-VAD) are commonly used as bridges to heart
ransplantation or ventricular recovery and, more recently,
ave demonstrated both mortality and quality of life benefit
s “destination therapy” in patients for whom heart trans-
Figure 5 Tissue Doppler Imaging and Assessment of Regional F
Apical 4-chamber view with tissue Doppler imaging showing regional analysis of th
opathy. Regions of interest (ROI) are drawn at the mid portions of the septal and l
graphically displayed over time.lantation is not an option (110). Candidates for VAD
lacement, however, require careful preoperative consider-
tion. Significant intracardiac shunts, such as an atrial septal
efect, will be exacerbated by LVAD placement, leading to
ignificant hypoxia (111). Furthermore, significant valvular
isease, especially significant aortic stenosis or aortic regur-
itation, must be detected to allow valve repair or replace-
ent before VAD implant. Decreased right ventricular
unction and high pulmonary pressures often necessitate
lacement of a bi-VAD. Preoperative echocardiography can
etect all of these disorders. After implantation, echocardi-
graphy can detect thrombus formation within the VAD
112) or other causes of inflow cannula obstruction. (Fig. 4)
oppler and color Doppler imaging can also detect signif-
cant inflow and outflow cannulae regurgitation and also
ssess aortic valve opening and insufficiency (113).
ew Horizons for Advanced
chocardiographic Techniques in HF
chocardiographic techniques applicable to HF patients are
dvancing rapidly. New techniques have been developed to
mage myocardial mechanics and provide more precise
easurements to guide therapeutic decisions. Although
RI is an established technique for measuring myocardial
echanics and obtaining highly accurate measurements of
ardiac size and structures, the evaluation of these parame-
ers by echocardiography is considerably more feasible for
ion
raction patterns of the septal and lateral walls in a patient with dilated cardiomy-
walls, and the contraction velocities within each ROI in the vertical plane areunct
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Echocardiographic Applications in HF July 31, 2007:381–96linical use, because it is widely available and repeat assess-
ent can be readily performed.
yocardial motion, strain, and strain rate. One of the
ost promising techniques, already used in daily clinical
ractice, is tissue Doppler imaging (TDI) (Fig. 5). Tissue
oppler imaging has been used with M-mode, 2D, and
ulse wave Doppler (114). The peak systolic myocardial
elocity, reflective of longitudinal myocardial fiber shorten-
ng, has been used to assess systolic function in HF. Yip
t al. (115) and Yu et al. (116) noted systolic abnormalities
Sm 4.4 m/s) with TDI in 38% to 52% of HF patients
ith normal EFs. Their findings suggest that systolic
yocardial velocity might provide a more accurate measure
f systolic dysfunction than EF. Many HF patients with
ormal EF might have systolic as well as diastolic HF. In
his setting, tissue velocity measures have demonstrated
ncremental (117,118) and, in a recent study, superior (119)
rognostic ability compared with standard echocardio-
raphic measures, including EF.
Tissue velocity measurements are susceptible to artifact
rom tethering and translational motion (i.e., displacement
f the entire heart is recorded as tissue motion of the specific
egment being measured). Strain imaging, derived from
issue velocity measurements, overcomes this limitation by
easuring actual deformation of the myocardium (expressed
Figure 6 Velocity Vector Imaging
The upper panels display radial and rotational mechanics of the left ventricle (LV)
in end-systole with the direction of the arrows pointing to a counter-clockwise rotat
velocities (red arrows). These velocities are automatically calculated at each locat
tation of the rotational motion at the base (B) of the LV and at the apex (C). The
(degrees of rotation). The apical rotation in this example is 7°, the minus sign d
Thus, the LV twist is 11°, and LV torsion is derived by dividing LV twist by the dists a percentage) in systole and diastole. Strain rate is the
nverse of the time to deformation. As measured in the
ongitudinal direction (base to apex in the apical views),
he normal values for strain are 15% to 25% and for strain
ate are 1 to 1.5 s1 (120). Like tissue velocity measures,
train and strain rate imaging detect abnormalities of
ystolic and diastolic function in patients with infiltrative
ardiomyopathies (121). In addition, Palka et al. (122)
escribed the use of strain rate to differentiate restrictive
ardiomyopathy (reduced early diastolic strain rate, com-
ared with normal hearts) from constrictive physiology
increased early diastolic strain rate).
The identification and measurement of dyssynchrony is
ne of the most widely published uses of tissue velocity,
train, and strain rate imaging in HF. The TDI techniques
redict echocardiographic and clinical response to bi-
entricular pacing with high sensitivity and specificity.
everal parameters have been used, such as an intersegmen-
al delay in peak systolic longitudinal motion between
egments (abnormal 60 to 65 ms) and the SD of time to
eak velocity of 12 segments (abnormal 30 to 31 ms)
123,124). Tissue Doppler imaging can identify the specific
egions involved in dyssynchrony as well as the magnitude
f dyssynchronous contraction. This information can be
vailable to guide specific placement of bi-ventricular pacing
ocity Vector Imaging (VVI). (A) Depiction of radial velocity vectors (yellow arrows)
the apex. Velocities that are orthogonal to these radial velocities are rotational
the arrows around the LV circumference. (B and C) Depiction of visual represen-
panels show the magnitude of the rotational motion at the apex and base
g counterclockwise rotation. The basal rotation in the clockwise direction is 4°.
etween the base and the apex in centimeters.by Vel
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July 31, 2007:381–96 Echocardiographic Applications in HFeads and assess response during long-term follow-up.
urthermore, as bi-ventricular pacemakers can be set with a
elay between right ventricular and LV activation, dyssyn-
hrony measures can been used to optimize these settings,
mproving intraventricular and interventricular synchrony
nd hemodynamic status (125).
issue tracking. The major limitation to TDI is Doppler
ngle dependency and problems in assessing regional LV
orsional dynamics. In particular, the rotational component of
ardiac contraction plays a significant role in LV ejection and
elaxation and is poorly imaged by most TDI techniques.
Newer techniques such as “speckle tracking” algorithms
nvolve identification of multiple unique patterns of echo-
ardiographic pixel intensity that are automatically tracked
hroughout the cardiac cycle. The angular displacement of
hese pixels can be plotted over time for the apex, mid
entricle, and basal segments. Each pixel’s angular displace-
ent is averaged to provide a measurement of both degree
nd direction of rotational motion for each segment (Fig. 6).
his method is not limited by angle dependency and
ompares favorably with MRI (126,127).
Figure 7 Real Time 3-Dimensional Echocardiographic Volume M
(A) A real time 3-dimensional full volume image is acquired in the apical 4-chambe
and blue lines) to isolate the left ventricle (LV) for analysis. (C) Application of an a
cast, LV cavity volumes can be calculated and tracked over the cardiac cycle. Stro
ics can be measured. (E) The cast can also be automatically divided into wall seg
enabling regional wall motion and dyssynchrony analyses.Although the prognostic significance of abnormal ven-
ricular torsion has not been validated in large studies,
easurement of rotational motion has shown promise as a
ensitive marker for cardiac ischemia (128) and loading
onditions (129) and might prove beneficial as a refined
easure of LV dysfunction in HF and regional and global
yssynchrony (130). As such, it might become an important
arker of the functional significance of remodeling and
everse remodeling in HF patients (131). It might also be
ble to detect early allograft rejection in transplant patients,
otentially circumventing the need for frequent myocardial
iopsies. In fact, when combined with 3D imaging tech-
iques, it might prove to be a more sensitive marker for
ccult LV dysfunction.
D echocardiography. Previously hampered by the need
or cumbersome off-line reconstruction of images, 3D
chocardiography has benefited from the development of
ew matrix array transducers that acquire full volume data
ets to allow real-time imaging (132). The ability to visu-
lize all LV walls contemporaneously prevents foreshorten-
ng of the LV cavity and allows analysis of regional
rements
. (B) The image can be cropped and rotated along multiple planes (red, green,
ted border detection algorithm yields a cast of the endocardium. (D) From the
me, end systolic and end diastolic volumes, ejection fraction, and filling dynam-
. (F) Regional/segmental volume changes can be tracked over the cardiac cycle,easu
r view
utoma
ke volu
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Echocardiographic Applications in HF July 31, 2007:381–96yocardial function (Fig. 7). No geometric assumptions are
equired in calculating volumes from a 3D image. In recent
tudies, 3D echocardiography demonstrated accurate global
nd regional assessments of LV size and function compared
ith the gold standard of MRI as well as lower intra- and
nter-observer variability than traditional techniques (133).
ugeng et al. (134) showed 3D imaging to be superior to
ardiac computed tomography in EF and volumes assess-
ent. Application of new endocardial border detection
echniques to 3D images might allow direct calculation of
V volumes and EF, leading to improved reproducibility
135). Mor-Avi et al. (136) demonstrated that, as in
olumetric assessments, 3D echocardiography is more ac-
urate and reproducible than methods for LV mass calcu-
ation, compared with the gold standard of MRI.
The 3D imaging of global and regional function and LV
olumes has not yet translated into clear improvements in or
redictions of clinical outcomes. Three-dimensional echo-
ardiography might, in the future, prove beneficial in several
reas. The improved precision in measuring EF might guide
ore appropriate selection of patients for ICD and CRT
herapy. Like TDI, 3D echocardiography can assess seg-
ental myocardial motion over time, thereby detecting and
haracterizing dyssynchrony. Three-dimensional echocardi-
graphy has been used in the functional assessment of mitral
nnular size and tenting volume and improves the echocar-
iographic measurement of mitral regurgitation (137). A
ecent review discusses these and other applications of 3D
chocardiography in imaging HF patients, such as assess-
ents of atrial size and of right ventricular size and function
138).
onclusions
chocardiography is well qualified to meet the growing
eed for noninvasive imaging in the HF population. Be-
ause HF patients often have more than 1 structural and/or
unctional abnormality contributing to their disease state,
chocardiography’s versatility in detecting valvular and peri-
ardial pathology along with myocardial disorders yields
bvious benefits. Doppler measurements provide important
nformation to direct management of volume status, diag-
ose and characterize HF with preserved systolic function,
nd identify patients at high risk for cardiovascular morbid-
ty and mortality. Not surprisingly, the underuse of echo-
ardiography in populations at significant risk for HF is
ssociated with adverse cardiovascular outcomes (139,140).
ssessment of LVEF in clinical HF is one of the primary
easures in a number of cardiovascular quality improve-
ent initiatives, including the AHA’s “Get with the Guide-
ines” and the ACC’s “Guidelines Applied in Practice”
141,142). Echocardiography is well suited to repeated
easurements of EF and LV mass in clinical trials and
outine patient care. In fact, the new HF guidelines recom-
end repeat echocardiography for HF patients withhanges in symptoms, a clinical event, or a treatment likelyo affect cardiac function (1). Echocardiography provides
mportant data for therapeutic decision-making, including
efining candidacy for medications, implantable cardiac
evices, and surgical procedures. New techniques for the
haracterization of ventricular mechanics and recent devel-
pments in 3D echocardiography hold great promise for
mproving the quality of care to the growing population of
F patients.
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